Survie améliorée avec l'inhibition de MEK dans le mélanome muté BRAF

Flaherty et al. (jeu,) ont étudié cette question.

www.synapsesocial.com/papers/69d97f6ac7f0c3ae80a3dbb9 — DOI: https://doi.org/10.1056/nejmoa1203421

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation· 2011 · 7,678 citations
2. Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review and Practice Guideline· 2012 · 54 citations
3. Toxicity and response criteria of the Eastern Cooperative Oncology Group· 1982 · 11,557 citations
4. Embryonic stem‐cell‐preconditioned microenvironment induces loss of cancer cell properties in human melanoma cells· 2011 · 25 citations
5. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.· 2010 · 121 citations